Simplify Logo
Amgen

Amgen

Biotech company creating biologic medicines

Key Account Manager - Cardiovascular

Full-TimePosted on 6/13/2026
$169.8k - $201.8k/yr
Mid, Senior, Expert
Bachelor's, Master's, MBA, PharmD, PhD
Austin, TX, USA+2 more

More locations: San Antonio, TX, USA | Tyler, TX, USA

In Person

Field-based territory covering Austin, San Antonio, and Tyler, Texas.

About the job

Requirements
  • A doctorate degree and 2 years of sales experience and/or related account management experience; or a master's degree and 4 years of such experience; or a bachelor's degree and 6 years of such experience.
  • The ability to understand and identify key staff and departments influencing biopharmaceutical product utilization and to maintain and grow relationships with key decision-makers.
  • The ability to identify and procure appropriate company resources to achieve account objectives.
  • The ability to analyze, interpret, and draw insights from clinic economics, financial performance, and varying data sources.
  • The ability to successfully navigate clinic reimbursement.
  • Interpersonal skills including networking, influencing, negotiation, presentation, and written and verbal communication.
  • The ability to work in a fast-paced environment, handle multiple competing priorities, work independently, and collaborate in teams.
  • Creative problem-solving skills, initiative, and the ability to impart energy and enthusiasm.
  • A broad range of computer skills.
Responsibilities
  • Assess and diagnose the current business environment in assigned accounts in relation to cardiovascular products and plan and execute actions for account success.
  • Develop and execute compliant strategies to reach difficult-to-access healthcare providers and accounts.
  • Maintain comprehensive account profiles, needs assessments, and strategic plans.
  • Meet routinely with opinion leaders and decision-makers in cardiology, lipidology, pharmacy, P&T committees, and health systems.
  • Present approved data and cardiovascular product messaging and deliver clinical messages in compliance with governing policies.
  • Ensure formulary adoption in targeted hospital accounts and coordinate pull-through and access activities with sales colleagues.
  • Monitor business performance across the cardiovascular portfolio.
  • Identify drivers and barriers and coordinate pull-through initiatives across field teams and matrixed partners.
  • Coordinate home-office engagement with customers and arrange approved promotional programs, displays, and hospital initiatives.
  • Build and develop professional relationships with hospital pharmacy, lipid clinical, heart failure clinical, quality, and finance decision-makers.
  • Partner with Organized Customer Team Regional Account Executives and Regional Medical Liaisons in shared accounts.
  • Coordinate with the Reimbursement Access Value team to support portfolio access.
  • Provide actionable field intelligence and recommendations to home-office and cardiovascular brand teams.
  • Provide field insights and recommendations to pricing, brand, and GPO teams.
  • Lead contract delivery, business reviews, and performance tracking.
  • Organize competitive responses, shape the environment, execute value/FDAMA 114 tools where appropriate, and support the value of innovation.
Desired Qualifications
  • Three or more years of account management and/or public payor experience.
  • An advanced degree such as an MPH, MBA, or PharmD, together with seven or more years of healthcare sales and/or marketing experience or related buying-process and decision-making experience.
  • Clinic, hospital, dyslipidemia, heart failure, access-environment, competitor, and industry experience.
  • Cardiology experience, including dyslipidemia, heart failure, and acute coronary syndromes.
  • Understanding of current trends in community cardiology practices.
  • Understanding of internal and external dynamics in dyslipidemia and heart failure, including inpatient-to-outpatient management, protocols, readmission programs, electronic management systems, performance and quality metrics, and congestive heart failure/interventional priorities.
  • District management experience.
  • Reimbursement and managed-care experience.
  • Experience with public payor and agency activities, including Local Coverage Determination processes.
  • Knowledge of hospital committee structures, P&T processes, treatment and discharge protocols, diagnosis-related groups, and hospital reimbursement processes.
  • Functional knowledge of Medicare and government agencies.
  • Knowledge of payor systems, billing, coding, reimbursement processes, and Centers for Medicare & Medicaid Services policies and processes.
  • Documented ability to work with a sales force to resolve payor-related issues.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
  • Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
  • MariTide now has nine ongoing and three planned Phase 3 studies across obesity.

What critics are saying

  • Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
  • FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
  • If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.

What makes Amgen unique

  • Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
  • IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
  • Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

INACTIVE